

the desire to find alternative therapies by both patients and physicians. However, we agree with Dr Rubin that we physicians should check our enthusiasm with the knowledge that this therapy has uncertain efficacy in IBD (3). Our first priority to patients should be the use of proven therapies and then advocating for clinical trials of FMT to identify the subset of IBD patients who may benefit most from it. In the meantime, we should be aware of what

our patients may be doing themselves and help document the outcomes.

CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

1. van Nood E, Vrieze A, Nieuwdorp M *et al*. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013;368:407–15.
2. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of *Clostridium difficile* infection: a systematic review. *J Clin Gastroenterol* 2014 (e-pub ahead of print).
3. Rubin D. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. *Am J Gastroenterol* 2013;108:1631–3.

¹Lenox Hill Hospital, New York, New York, USA.
Correspondence: Arun Swaminath, MD, Lenox Hill Hospital, 100 East 77th Street, 2nd Floor, New York, New York 10075, USA.
E-mail: aswaminath@nshs.edu